Lars Neumann
Overview
Explore the profile of Lars Neumann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
485
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kalliokoski T, Kettunen H, Kumpulainen E, Kettunen E, Thieulin-Pardo G, Neumann L, et al.
Bioorg Med Chem Lett
. 2023 Aug;
94:129450.
PMID: 37591318
Methionine adenosyltransferase 2A (MAT2A) has been indicated as a drug target for oncology indications. Clinical trials with MAT2A inhibitors are currently on-going. Here, a structure-based virtual screening campaign was performed...
2.
Hassenruck F, Farina-Morillas M, Neumann L, Landini F, Blakemore S, Rabipour M, et al.
Commun Biol
. 2023 Jun;
6(1):603.
PMID: 37277510
Targeting the PI3K isoform p110δ against B cell malignancies is at the mainstay of PI3K inhibitor (PI3Ki) development. Therefore, we generated isogenic cell lines, which express wild type or mutant...
3.
Pu Q, Zhang H, Guo L, Cheng M, Doty A, Ferguson H, et al.
ACS Med Chem Lett
. 2020 Aug;
11(8):1548-1554.
PMID: 32832022
Indoleamine-2,3-dioxygenase 1 (IDO1) inhibition and its combination with immune checkpoint inhibitors like have drawn considerable attention from both academia and the pharmaceutical industry. Here, we describe the discovery of a...
4.
Jaecker V, Neumann L, Shafizadeh S, Koenen P, Kanakamedala A, Tjardes T
Knee Surg Sports Traumatol Arthrosc
. 2019 Feb;
27(11):3432-3440.
PMID: 30715593
Purpose: In medial patellofemoral ligament (MPFL) reconstruction, it remains controversial whether more accurate femoral tunnel positioning is correlated with improved clinical outcomes. The purpose was to verify the accuracy of...
5.
Leenen E, Neumann L, Harth A, Jorres A, Weidemann A
Clin Kidney J
. 2018 Oct;
11(5):724-725.
PMID: 30288269
Peripheral arterial disease and diabetic foot syndrome are common comorbidities in dialysis patients. These conditions are treated with intermittent vacuum therapy in order to increase angiogenesis and perfusion. Some devices...
6.
Hassenruck F, Knodgen E, Gockeritz E, Midda S, Vondey V, Neumann L, et al.
Biomed Res Int
. 2018 May;
2018:1023490.
PMID: 29750146
The antibody-dependent cell-mediated cytotoxicity (ADCC) of the anti-CD20 monoclonal antibodies (mAbs) rituximab and obinutuzumab against the cell line Raji and isolated CLL cells and its potential impairment by kinase inhibitors...
7.
Gockeritz E, Vondey V, Guastafierro A, Pizevska M, Hassenruck F, Neumann L, et al.
Br J Haematol
. 2017 Jun;
178(6):949-953.
PMID: 28573668
To elucidate their mechanism of action, inhibitors of Bruton tyrosine kinase (BTK) and resistant BTK mutants were employed to dissect target-dependent cellular functions. BTK-C481S and -T474I, expressed in Ramos and...
8.
Krause G, Baki I, Kerwien S, Knodgen E, Neumann L, Gockeritz E, et al.
Br J Haematol
. 2015 Aug;
173(5):791-4.
PMID: 26271483
No abstract available.
9.
Schiebel J, Radeva N, Koster H, Metz A, Krotzky T, Kuhnert M, et al.
ChemMedChem
. 2015 Aug;
10(9):1511-21.
PMID: 26259992
Fragment-based lead discovery is gaining momentum in drug development. Typically, a hierarchical cascade of several screening techniques is consulted to identify fragment hits which are then analyzed by crystallography. Because...
10.
Gockeritz E, Kerwien S, Baumann M, Wigger M, Vondey V, Neumann L, et al.
Int J Cancer
. 2015 Apr;
137(9):2234-42.
PMID: 25912635
Pharmacological inhibition of phosphatiylinositide-3-kinase (PI3K)-mediated signaling holds great promise for treating chronic lymphocytic leukemia (CLL). Therefore we assessed three structurally related PI3K inhibitors targeting the PI3K-δ isoform for their ability...